Full Review,ligand prolongs the half-life of several bioactive peptides more than 25-fold

The field of medicine is continually seeking ways to improve the efficacy and patient experience of therapeutic treatments. A significant hurdle in the development of many peptide therapeutics has been their inherently short circulating half-life. This often necessitates frequent injections, impacting patient adherence and overall treatment effectiveness. However, advancements in peptide half-life extension are rapidly overcoming these limitations, promising a new era for peptide-based medicines.

The challenge stems from the body's natural processes. Peptide therapeutics often suffer from short half-lives due to rapid degradation by enzymes and swift clearance from the bloodstream. This means that a therapeutic dose may be eliminated from the body before it can exert its full beneficial effect. To address this, researchers have developed sophisticated strategies for half-life extension, aiming to keep the therapeutic peptides in circulation for longer periods.

One of the most prominent and established half-life extension strategies involves the conjugation to albumin. Albumin, the most plentiful serum protein in the blood, has a naturally long half-life, typically around 19 days in humans. By attaching therapeutic peptides to albumin, either directly or through a linker molecule, their residence time in the body can be significantly prolonged. This approach leverages the natural protective mechanisms of albumin, effectively allowing it to "piggy-back" the peptide onto a longer-lived carrier. Studies have shown that serum albumin binding is a key approach to extend the half-life of peptide drugs. For instance, fusing peptide drugs with HSA (Human Serum Albumin) can significantly extend their half-life. A notable example of this is albighztide, a therapeutic developed by GlaxoSmithKline.

Beyond albumin conjugation, other innovative methods are proving highly effective. Lipidation has emerged as a preeminent alternative to PEGylation (conjugation with polyethylene glycol) for achieving half-life extension of biopharmaceuticals through chemical modification. Lipidation involves attaching fatty acid chains to the peptide, which promotes non-covalent interactions with plasma proteins and cellular membranes, thereby slowing down clearance.

Furthermore, the development of novel ligand molecules has opened new avenues for peptide half-life extension. Researchers have engineered specific ligands that can bind with high affinity to albumin or other circulatory components. These ligands can then be attached to peptides, acting as a bridge to extend their presence in the bloodstream. In some cases, a new ligand could potentially extend the half-life of peptides from mere minutes to several days. One study demonstrated that a ligand prolongs the half-life of several bioactive peptides more than 25-fold in vivo. This ability to extend the life of peptides has future applications in areas like imaging and the treatment of tumors.

Another promising technique involves the use of peptide and protein tags. These specialized tags can be engineered to enhance the pharmacokinetic profiles of biological drugs by increasing their half-life. One such technology, XTENylation, has shown to effectively extend the half-life of a wide spectrum of biologically active molecules, thereby broadening their therapeutic potential. For example, ISOXTEND® has demonstrated the ability to extend the half-life of VHH-based therapeutics up to 26 hours in mice, which approximates to 16-19 days in humans.

The pursuit of peptide half-life extension is crucial for unlocking the full therapeutic potential of these versatile molecules. By implementing these advanced strategies, researchers are not only improving the in vivo half-life extension of peptide pharmaceuticals but also significantly enhancing their overall pharmacokinetic profiles. These advancements are leading to improved therapeutic potency and a more convenient treatment regimen for patients, ultimately contributing to better health outcomes. The ongoing research and development in enhancing circulatory half-lives are poised to revolutionize the landscape of peptide therapeutics.